^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | crenolanib (ARO-002) (FLT3 inhibitor, PDGFR α inhibitor, PDGFR β inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Excerpt:
...FLT3 mutation positive (ITD, TKD or other) 3....
Trial ID:
Source:
Title:
"Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) "
Published date:
11/04/2020
Excerpt:
Complete remissions with full count recovery (CR) were achieved in 10 of 15 patients after just one cycle of induction chemotherapy. Two patients achieved a complete remission after reinduction for an overall CR rate of 86%....This safety study shows that crenolanib can be combined at full doses (100mg TID) for the duration of 7+3 induction, consolidation, and maintenance in older patients with FLT3 mutant AML.
Secondary therapy:
cytarabine + idarubicin + daunorubicin
DOI:
https://doi.org/10.1182/blood-2019-130536
Trial ID:
Source:
Title:
Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)
Published date:
11/06/2019
Excerpt:
Ten of 14 patients were able to receive full doses of crenolanib during induction...Complete remissions with full count recovery (CR) were achieved in 10 of 15 patients after just one cycle of induction chemotherapy...This safety study shows that crenolanib can be combined at full doses (100mg TID) for the duration of 7+3 induction, consolidation, and maintenance in older patients with FLT3 mutant AML.
DOI:
https://doi.org/10.1182/blood-2019-130536
Source:
Title:
Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
Published date:
11/06/2019
Excerpt:
...a phase II study of crenolanib combined with chemotherapy...Twenty-three of 27 patients (85%) achieved complete remission, all of whom required only 1 cycle of induction chemotherapy. Nineteen of 27 patients remain alive and free of disease with a median follow-up of 29.3 months (Figure 1). These clinical data suggest that this combination might improve outcomes in younger patients with newly diagnosed FLT3-mutant AML.
DOI:
10.1182/blood-2019-130863
Trial ID:
